Header Logo

DAVID MATHAI

TitleClinical Assistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Psychiatry & Behavioral Sciences
Address1977 Butler Blvd
Houston, 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mathai DS, Roberts DE, Nayak SM, Sepeda ND, Lehrner A, Johnson MW, Lowe MX, Jackson H, Garcia-Romeu A. Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use. J Psychoactive Drugs. 2025 Feb 07; 1-12. PMID: 39921237.
      Citations:    Fields:    
    2. Wang E, Mathai DS, Gukasyan N, Nayak S, Garcia-Romeu A. Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Sci Rep. 2024 11 14; 14(1):28022. PMID: 39543323; PMCID: PMC11564663.
      Citations:    Fields:    Translation:Humans
    3. Mathai DS. Learning how to make use of dissociative therapies. Int Rev Psychiatry. 2024 Dec; 36(8):856-868. PMID: 39980215.
      Citations:    Fields:    
    4. Mathai DS, Hull TD, Vando L, Malgaroli M. At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data. J Affect Disord. 2024 Sep 15; 361:198-208. PMID: 38810787; PMCID: PMC11284959.
      Citations: 2     Fields:    Translation:Humans
    5. Mathai DS, Hilbert S, Sepeda ND, Strickland JC, Griffiths RR, Garcia-Romeu A. Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers. Psychedelic Med (New Rochelle). 2023 Dec 01; 1(4):241-252. PMID: 38152462; PMCID: PMC10750378.
      Citations: 1     
    6. Nayak SM, Jackson H, Sepeda ND, Mathai DS, So S, Yaffe A, Zaki H, Brasher TJ, Lowe MX, Jolly DRP, Barrett FS, Griffiths RR, Strickland JC, Johnson MW, Jackson H, Garcia-Romeu A. Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey. Front Psychiatry. 2023; 14:1199642. PMID: 37795509; PMCID: PMC10545967.
      Citations:    
    7. Mathai DS, Nayak SM, Yaden DB, Garcia-Romeu A. Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine. Psychopharmacology (Berl). 2023 Apr; 240(4):827-836. PMID: 36729145.
      Citations:    
    8. Mathai DS, Yaden DB, O'Donnell KC. The conundrum of therapeutic intoxication. Br J Psychiatry. 2022 08; 221(2):496-497. PMID: 35848383.
      Citations:    
    9. Mathai DS, Lee SM, Mora V, O'Donnell KC, Garcia-Romeu A, Storch EA. Mapping consent practices for outpatient psychiatric use of ketamine. J Affect Disord. 2022 09 01; 312:113-121. PMID: 35753499.
      Citations:    Fields:    Translation:Humans
    10. Mathai DS, Mora V, Garcia-Romeu A. Toward Synergies of Ketamine and Psychotherapy. Front Psychol. 2022; 13:868103. PMID: 35401323; PMCID: PMC8992793.
      Citations:    
    11. Guzick AG, Leong AW, Dickinson EM, Schneider SC, Zopatti K, Manis J, Meinert AC, Barth AM, Perez M, Campo DM, Weinzimmer SA, Cepeda SL, Mathai D, Shah A, Goodman WK, Salloum A, Kennedy S, Ehrenreich-May J, Storch EA. Brief, parent-led, transdiagnostic cognitive-behavioral teletherapy for youth with emotional problems related to the COVID-19 pandemic. J Affect Disord. 2022 Mar 15; 301:130-137. PMID: 35031335; PMCID: PMC8752168.
      Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
    12. Barth AM, Meinert AC, Zopatti KL, Mathai D, Leong AW, Dickinson EM, Goodman WK, Shah AA, Schneider SC, Storch EA. A Qualitative Inquiry of Parents' Observations of Their Children's Mental Health Needs During the COVID-19 Pandemic. Child Health Care. 2022; 51(2):213-234. PMID: 35530015; PMCID: PMC9071000.
      Citations:    
    13. Mathai DS, McCathern AG, Guzick AG, Schneider SC, Weinzimmer SA, Cepeda SL, Garcia-Romeu A, Storch EA. Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. J Child Adolesc Psychopharmacol. 2021 10; 31(8):553-561. PMID: 34665021.
      Citations: 1     Fields:    Translation:Humans
    14. McCathern AG, Mathai DS, Cho RY, Goodman WK, Storch EA. Deep transcranial magnetic stimulation for obsessive compulsive disorder. Expert Rev Neurother. 2020 10; 20(10):1029-1036. PMID: 32684005.
      Citations: 2     Fields:    Translation:Humans
    15. Mathai DS, Meyer MJ, Storch EA, Kosten TR. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. J Affect Disord. 2020 03 01; 264:123-129. PMID: 32056741.
      Citations: 14     Fields:    Translation:Humans
    16. Verrico CD, Mathai DS, Gu H, Sampson AR, Lewis DA. Recovery from impaired working memory performance during chronic ?-9-tetrahydrocannabinol administration to adolescent rhesus monkeys. J Psychopharmacol. 2020 02; 34(2):211-220. PMID: 31621487; PMCID: PMC8173701.
      Citations: 4     Fields:    Translation:Animals
    17. Holst M, Mathai DS, Patel MM, Rodgman C, Keller J, Hussain MZ, De La Garza R, Kosten TR, Verrico CD. Use of Guanfacine for Cannabis Use Disorder and Related Symptomology. Am J Addict. 2019 11; 28(6):455-464. PMID: 31483544.
      Citations: 2     Fields:    Translation:Humans
    18. Mathai DS, Holst M, Rodgman C, Haile CN, Keller J, Hussain MZ, Kosten TR, Newton TF, Verrico CD. Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study. J Neuropsychiatry Clin Neurosci. 2018; 30(1):66-76. PMID: 28641496.
      Citations: 2     Fields:    Translation:Humans
    19. Mathai DS, Verrico CD, Shorter D, Coverdale JH, Kosten TR. "Just one bad high:" considering synthetic cannabinoid outcome expectancies in adolescents. Am J Addict. 2016 12; 25(8):620-622. PMID: 27749024.
      Citations:    Fields:    
    20. Mathai D, Gordon M, Muchmore P, Matorin A, Shah A, Moukaddam N. Paradoxical increase in synthetic cannabinoid emergency-related presentations after a citywide ban: Lessons from Houston, Texas. Bull Menninger Clin. 2016; 80(4):357-370. PMID: 27936903.
      Citations:    Fields:    Translation:Humans
    MATHAI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (71)
    Explore
    _
    Co-Authors (11)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _